{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:16Z","timestamp":1792427776188,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","award":["02NUK047D"],"award-info":[{"award-number":["02NUK047D"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2762\/1"],"award-info":[{"award-number":["GRK2762\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK1739\/2"],"award-info":[{"award-number":["GRK1739\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WI 4702\/2-1 WI 4702\/2-1"],"award-info":[{"award-number":["WI 4702\/2-1 WI 4702\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.neo.2023.100892","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T11:57:51Z","timestamp":1680350271000},"page":"100892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis \u2013 The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging"],"prefix":"10.1016","volume":"39","author":[{"given":"Nika","family":"Guberina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-216X","authenticated-orcid":false,"given":"Florian","family":"Wirsd\u00f6rfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Jendrossek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2023.100892_bib0001","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0002","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0097","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40(12):","author":"Spigel","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0004","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.09.013","article-title":"Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1\/2 trial","volume":"68","author":"Levy","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0005","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2023.100892_bib0006","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3389\/fimmu.2018.03154","article-title":"Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment","volume":"9","author":"Darragh","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2023.100892_bib0007","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0008","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2023.100892_bib0009","article-title":"Crossed pathways for radiation-induced and immunotherapy-related lung Injury","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2023.100892_bib0010","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2023.100892_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010024","article-title":"Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity?","volume":"20","author":"Wirsdorfer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2023.100892_bib0012","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.neo.2023.100892_bib0015","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/imr.12568","article-title":"Immune recognition of irradiated cancer cells","volume":"280","author":"Wennerberg","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neo.2023.100892_bib0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-16-0037","article-title":"Toward precision radiotherapy for use with immune checkpoint blockers","volume":"24","author":"Vanpouille-Box","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2023.100892_bib0018","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fgene.2016.00147","article-title":"DNA Damage response and immune defense: links and mechanisms","volume":"7","author":"Nakad","year":"2016","journal-title":"Front. Genet."},{"key":"10.1016\/j.neo.2023.100892_bib0019","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2741\/4488","article-title":"Interconnection between DNA damage, senescence, inflammation, and cancer","volume":"22","author":"Wunderlich","year":"2017","journal-title":"Front. Biosci."},{"key":"10.1016\/j.neo.2023.100892_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13014-017-0865-1","article-title":"Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades","volume":"12","author":"Wirsdorfer","year":"2017","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523097","article-title":"Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells","volume":"8","author":"Krombach","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2023.100892_bib0022","doi-asserted-by":"crossref","first-page":"14995","DOI":"10.1038\/ncomms14995","article-title":"Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression","volume":"8","author":"Contrepois","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2023.100892_bib0023","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","article-title":"Barriers to radiation-induced in situ tumor vaccination","volume":"8","author":"Wennerberg","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2023.100892_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.neo.2023.100892_bib0026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","article-title":"The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0027","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.neo.2023.100892_bib0028","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1172\/JCI122010","article-title":"DNA repair defects and implications for immunotherapy","volume":"128","author":"Bever","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2023.100892_bib0029","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.adro.2018.08.017","article-title":"The DNA damage response in immunotherapy and radiation","volume":"3","author":"Samstein","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0030","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190224","article-title":"Harnessing radiation to improve immunotherapy: better with particles?","volume":"93","author":"Durante","year":"2020","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.neo.2023.100892_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7150\/ijbs.12009","article-title":"Ionizing radiation impairs T cell activation by affecting metabolic reprogramming","volume":"11","author":"Li","year":"2015","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.neo.2023.100892_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/imr.12703","article-title":"Metabolic regulation of innate and adaptive lymphocyte effector responses","volume":"286","author":"Joseph","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neo.2023.100892_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cmet.2017.08.012","article-title":"Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses","volume":"26","author":"Thwe","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.neo.2023.100892_bib0034","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/annonc\/mdx069","article-title":"Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA\/B non-small-cell lung cancer: secondary analysis of a randomized trial","volume":"28","author":"Guberina","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2022.06.005","article-title":"Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: a systematic literature review and meta-analysis","volume":"174","author":"Kuang","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The Phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0037","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neo.2023.100892_bib0038","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0039","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2015.01.045","article-title":"Immunological markers that predict radiation toxicity","volume":"368","author":"Sprung","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2023.100892_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semradonc.2014.07.007","article-title":"Radiation and inflammation","volume":"25","author":"Schaue","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093279","article-title":"Cellular senescence in the lung: the central role of senescent epithelial cells","volume":"21","author":"Hansel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2023.100892_bib0042","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2023.100892_bib0043","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0044","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-030-41008-7_13","article-title":"Immune-related adverse events: pneumonitis","volume":"1244","author":"Zhong","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neo.2023.100892_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.20892\/j.issn.2095-3941.2020.0102","article-title":"The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients","volume":"17","author":"Zhai","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0046","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neo.2023.100892_bib0047","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0048","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.neo.2023.100892_bib0049","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"Laubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2023.100892_bib0051","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0052","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-020-01718-3","article-title":"Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications","volume":"18","author":"Teng","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.neo.2023.100892_bib0053","doi-asserted-by":"crossref","first-page":"e1589","DOI":"10.1634\/theoncologist.2020-0266","article-title":"A multidisciplinary approach for patients with preexisting lung diseases and immune checkpoint inhibitor toxicities","volume":"25","author":"Naidoo","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.neo.2023.100892_bib0054","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0055","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0056","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: current evidence","volume":"21","author":"Arroyo-Hernandez","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0057","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0058","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.ijrobp.2012.01.018","article-title":"Dose\u2013volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer","volume":"83","author":"Matsuo","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neo.2023.100892_bib0059","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4143\/crt.2014.180","article-title":"Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.neo.2023.100892_bib0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1748-717X-5-32","article-title":"Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy","volume":"5","author":"Yamashita","year":"2010","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0061","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0062","first-page":"541","article-title":"The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance","volume":"180","author":"Rube","year":"2004","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.neo.2023.100892_bib0063","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0360-3016(00)00482-X","article-title":"Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation","volume":"47","author":"Rube","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neo.2023.100892_bib0064","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","article-title":"Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MOT.0000000000001036","article-title":"Immune checkpoint inhibitors in kidney transplantation","volume":"28","author":"Alzahrani","year":"2023","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"10.1016\/j.neo.2023.100892_bib0066","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers-emerging strategies for clinical management","author":"Ferrandiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.neo.2023.100892_bib0067","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad010","article-title":"Systematic review with meta-analysis: the impact of cancer treatments on the disease activity of inflammatory bowel diseases","author":"Grimsdottir","year":"2023","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.neo.2023.100892_bib0068","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.neo.2023.100892_bib0069","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.neo.2023.100892_bib0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0071","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.neo.2023.100892_bib0072","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1093\/oncolo\/oyac220","article-title":"Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge","volume":"27","author":"Park","year":"2022","journal-title":"Oncologist"},{"issue":"Suppl 118","key":"10.1016\/j.neo.2023.100892_bib0073","first-page":"114","article-title":"Sicca\/Sjogren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.neo.2023.100892_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0075","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2023.100892_bib0076","first-page":"9","article-title":"HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis","author":"Correale","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neo.2023.100892_bib0077","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"treatment characteristics and real-world progression-free survival in patients with unresectable stage III nsclc who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0078","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0079","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0081","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.lungcan.2011.05.010","article-title":"Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer","volume":"74","author":"Phernambucq","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0082","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2023.100892_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0084","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2021.04.045","article-title":"Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy","volume":"153","author":"Dearden","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2023.100892_bib0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0360-3016(95)90159-0","article-title":"LENT SOMA scales for all anatomic sites","volume":"31","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neo.2023.100892_bib0086","series-title":"Common terminology criteria for adverse events. Version 5.0","author":"UDo","year":"2020"},{"key":"10.1016\/j.neo.2023.100892_bib0087","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.neo.2023.100892_bib0088","series-title":"BMJ Case Rep.","article-title":"Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy","author":"Andruska","year":"2018"},{"key":"10.1016\/j.neo.2023.100892_bib0089","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.neo.2023.100892_bib0090","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2023.100892_bib0091","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2023.100892_bib0092","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society Research Statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.neo.2023.100892_bib0093","first-page":"10","article-title":"Radiation pneumonitis: old problem","author":"Jain","year":"2018","journal-title":"New Tricks Cancers"},{"key":"10.1016\/j.neo.2023.100892_bib0094","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fimmu.2017.00506","article-title":"immunological aspect of radiation-induced pneumonitis, current treatment strategies, and future prospects","volume":"8","author":"Kainthola","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2023.100892_bib0095","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/clinpract11030056","article-title":"Radiation-induced lung injury-current perspectives and management","volume":"11","author":"Rahi","year":"2021","journal-title":"Clin. Pract."},{"key":"10.1016\/j.neo.2023.100892_bib0096","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/pro6.1169","article-title":"Chinese expert consensus on diagnosis and treatment of radiation pneumonitis","volume":"6","author":"Zhou","year":"2022","journal-title":"Precis. Radiat. Oncol."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558623000179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558623000179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:40:54Z","timestamp":1777617654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558623000179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":97,"alternative-id":["S1476558623000179"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2023.100892","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis \u2013 The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2023.100892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100892"}}